You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dato-DXd

Showing 1 - 25 of 61
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Stage IV Trial in Vienna (Datopotamab deruxtecan)

Recruiting
  • Breast Cancer Stage IV
  • Datopotamab deruxtecan
  • Vienna, Austria
    AKH Universitaetsklinikum Vienna, Department f. Internal medicin
May 19, 2023

Metastatic Non Small Cell Lung Cancer Trial in Japan (Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Datopotamab Deruxtecan
  • +4 more
  • Fukuoka, Japan
  • +3 more
Jan 13, 2023

Advanced or Metastatic NSCLC Trial in Worldwide (Datopotamab deruxtecan, Durvalumab, Carboplatin)

Recruiting
  • Advanced or Metastatic NSCLC
  • Datopotamab deruxtecan
  • +4 more
  • Santa Ana, California
  • +15 more
Dec 13, 2022

NSCLC, Triple Negative Breast Cancer Trial in China (Datopotamab Deruxtecan (Dato-DXd))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Cancer
  • Datopotamab Deruxtecan (Dato-DXd)
  • Beijing, China
  • +27 more
Aug 11, 2022

Advanced or Metastatic NSCLC Trial in Worldwide (Datopotamab deruxtecan, Pembrolizumab, Carboplatin)

Recruiting
  • Advanced or Metastatic NSCLC
  • Datopotamab deruxtecan
  • +3 more
  • Scottsdale, Arizona
  • +24 more
Jun 3, 2022

Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Datopotamab Deruxtecan, Pembrolizumab)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Chandler, Arizona
  • +32 more
Aug 12, 2022

Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Datopotamab deruxtecan

Not yet recruiting
  • Endometrial Cancer
  • +4 more
  • Datopotamab deruxtecan (Dato-DXd)
  • +8 more
  • Los Angeles, California
  • +52 more
Aug 3, 2022

Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Dato-DXd
  • +6 more
  • Duarte, California
  • +111 more
Oct 23, 2023

Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Pembrolizumab)

Not yet recruiting
  • Breast Cancer
  • Dato-DXd
  • +9 more
  • Jonesboro, Arkansas
  • +142 more
Oct 31, 2023

Breast Cancer Trial in Worldwide (Dato-DXd, Capecitabine, Gemcitabine)

Active, not recruiting
  • Breast Cancer
  • Dato-DXd
  • +4 more
  • Duarte, California
  • +172 more
Dec 1, 2022

Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Capecitabine)

Recruiting
  • Breast Cancer
  • Dato-DXd
  • +3 more
  • Gilbert, Arizona
  • +165 more
Jan 17, 2023

Breast Cancer Trial in Worldwide (Dato-DXd, Paclitaxel, Nab-paclitaxel)

Recruiting
  • Breast Cancer
  • Dato-DXd
  • +5 more
  • Duarte, California
  • +260 more
Jan 19, 2023

Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab

Recruiting
  • Hormone Receptor Positive Breast Cancer
  • +2 more
  • Datopotamab Deruxtecan (Dato-DXd)
  • Los Angeles, California
  • +13 more
Jun 21, 2022

Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

Recruiting
  • Breast Neoplasms
  • +10 more
  • Standard Therapy
  • +32 more
  • Birmingham, Alabama
  • +35 more
Nov 17, 2022

NSCLC Trial in Worldwide (Datopotamab deruxtecan, Durvalumab, Carboplatin)

Recruiting
  • NSCLC
  • Datopotamab deruxtecan
  • +6 more
  • Phoenix, Arizona
  • +227 more
Jan 17, 2023

Ovarian Cancer, Breast Cancer, Pancreatic Cancer Trial in Worldwide (AZD5305, Paclitaxel, Carboplatin)

Recruiting
  • Ovarian Cancer
  • +12 more
  • San Francisco, California
  • +44 more
Jul 12, 2022

NSCLC Trial in Worldwide (DS-1062a, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Chandler, Arizona
  • +203 more
Jun 9, 2022

Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

Recruiting
  • Metastatic Breast Cancer
  • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
  • Rome, Italy
    Fondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Previously Treated Advanced/Metastatic HER2-positive Breast

Recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Naples, Italy
  • +17 more
Jan 31, 2023

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab deruxtecan
  • +9 more
  • Malmö, Sweden
  • +6 more
Jun 8, 2023

Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

Not yet recruiting
  • Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab-Deruxtecan (T-DXd)
  • (no location specified)
Sep 20, 2023

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023